Ginkgo Bioworks Holdings Inc (NYSE: DNA): Hunting Genuine Value In Market Debris

Currently, there are 1.53B common shares owned by the public and among those 1.34B shares have been available to trade.

The company’s stock has a 5-day price change of 1.75% and -34.46% over the past three months. DNA shares are trading -31.36% year to date (YTD), with the 12-month market performance down to -3.33% lower. It has a 12-month low price of $1.03 and touched a high of $2.55 over the same period. DNA has an average intraday trading volume of 22.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.68%, -8.14%, and -28.73% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares accounts for 58.54% of the company’s 1.53B shares outstanding.

It has a market capitalization of $2.36B and a beta (3y monthly) value of 1.35. The earnings-per-share (ttm) stands at -$0.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.95% over the week and 7.27% over the month.

Analysts forecast that Ginkgo Bioworks Holdings Inc (DNA) will achieve an EPS of -$0.08 for the current quarter, -$0.08 for the next quarter and -$0.27 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.11 a year ago. Earnings per share for the fiscal year are expected to increase by 30.58%, and 14.75% over the next financial year.

Looking at the support for the DNA, a number of firms have released research notes about the stock. Raymond James stated their Mkt Perform rating for the stock in a research note on November 14, 2023, with the firm’s price target at $3.50-$2.50. Berenberg on their part issued Buy rating on November 29, 2022.

Most Popular

Related Posts